Efficacy and toxicity of decitabine in patients with acute myeloid leukemia (aml): a multicenter real-world experience
Acute myeloid leukemia (AML) treatment options for older patients with AML either for first line or in relapsed/refractory cases are limited, with very poor outcomes (1 –3). Elderly patients are often ineligible for intensive anti-leukemic chemotherapy (CHT) or participation to clinical trial due to poor performance status and/or organ dysfunction. This population has an increased incidence of pre-existing myelodysplastic syndrome (MDS), unfavorable cytogenetics and multi-drug-resistant phenotype, any of which can impair the efficacy of intensive antileukemic CHT (1–3).
Source: Leukemia Research - Category: Hematology Authors: Carla Fil ì, Anna Candoni, Maria Elena Zannier, Jacopo Olivieri, Silvia Imbergamo, Manuela Caizzi, Gianpaolo Nadali, Eros Di Bona, Anna Ermacora, Michele Gottardi, Davide Facchinelli, Rosanna Ciancia, Davide Lazzarotto, Maria Vittoria Dubbini, Gianluca F Tags: Research paper Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Chemotherapy | Clinical Trials | Hematology | Leukemia | Myelodysplastic Syndrome | Toxicology